Effects of L/N-Type Calcium Channel Antagonist, Cilnidipine on Progressive Renal Injuries in Dahl Salt-Sensitive Rats(Pharmacology)
スポンサーリンク
概要
- 論文の詳細を見る
The sympathetic nerve activity plays an important role on the renal function through the vasoactive system and the renin-angiotensin system. Although interest in the renal protective effects of anti-sympathetic agents has been increased, there are not enough data to clarify this efficiency. Therefore, we investigated the effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injury in Dahl salt-sensitive (Dahl S) rats. Male Dahl S rats (6 weeks of age) were fed a high salt (4% NaCl) diet. They were divided into groups with similar blood pressure at 12 weeks of age and they received vehicle (n=7) or cilnidipine (30mg/kg/d as food admix, n=9) for 8 weeks. Cilnidipine treatment suppressed the increase in systolic blood pressure. Although urinary protein excretion was not influenced, cilnidipine inhibited the increase in blood urea nitrogen and decrease in creatinine clearance. Histological investigation revealed that progression of gromerular sclerosis was inhibited in cilnidipine treatment group. Of notes, cilnidipine reduced plasma norepinephrine level and plasma rennin activity compared with vehicle-treated Dahl S rats. These data indicated that cilnidipine has suppressive effects against progressive renal injury in Dahl S rats. This effect is not only explained by the L-type calcium channel blocking action that lowered blood pressure, but also partially explained by the N-type calcium channel blocking action that lead to suppression of the sympathetic nerve activity and renin-angiotensin system.
- 公益社団法人日本薬学会の論文
- 2006-05-01
著者
-
TAKAHARA Akira
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc.
-
Takahara Akira
Pharmaceutical Research Laboratories Ajinomoto Co. Inc.
-
Konda Tomoyuki
Pharmaceutical Research Laboratories Ajinomoto Co. Inc.
-
YAMAMOTO Hiroshi
Pharmaceuticals Research Laboratories, Fujirebio Inc.
-
ENOMOTO Azusa
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc.
-
Enomoto Azusa
Pharmaceutical Research Laboratories Ajinomoto Co. Inc.
-
Yamamoto Hiroshi
Pharmaceutical Res. Laboratories Ajinomoto Co. Inc.
-
Yamamoto Hiroshi
Pharmaceutical Research Laboratories Ajinomoto Co. Inc.
関連論文
- In Vivo Antiarrhythmic Profile of AP-792 Assessed in Different Canine Arrhythmia Models
- Comparison of the Electropharmacological Effects of Verapamil and Propranolol in the Halothane-Anesthetized In Vivo Canine Model Under Monophasic Action Potential Monitoring
- Aminopeptidase N/CD13 Regulates the Fetal Liver Microenvironment of Hematopoiesis(Miscellaneous)
- Cardiovascular Effects of an L/N-type Ca^ Channel Blocker Cilnidipine Assessed in the Chronic Atrioventricular Conduction Block Dogs
- N- Plus L-Type Ca^ Channel Blocker Cilnidipine Decreased the Proarrhythmic Potential of the Canine Sudden Cardiac Death Model
- In Vitro and ex Vivo Ca-Antagonistic Effect of 2-Methoxyethyl (E)-3-phenyl-2-propen-1-yl (±)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate (FRC-8653), a New Dihydropyridine Derivative
- Neuronal Ca^ Channel Blocking Action of an Antihypertensive Drug, Cilnidipine, in IMR-32 Human Neuroblastoma Cells
- Effects of L/N-Type Calcium Channel Antagonist, Cilnidipine on Progressive Renal Injuries in Dahl Salt-Sensitive Rats(Pharmacology)
- Neuroprotective Effects of a Dual L/N-type Ca^ Channel Blocker Cilnidipine in the Rat Focal Brain Ischemia Model(Pharmacology)
- Cardiac Ca^ Channel-Blocking Effects of the Cyproheptadine Derivative AH-1058 in Isolated Guinea Pig Cardiomyocytes
- Utilization of Telemetry System to Assess the Cardiovascular Profile of AH-1058, a New Cardioselective Ca^ Channel Blocker, in Conscious Dogs
- Electrophysiological and Cardiohemodynamic Effects of AH-1058, a New Type Calcium Channel Blocker, Assessed by the In Vivo Canine Model